The company is focused on the development of the world's first, IOL-mounted, controlled-release drug delivery platform capable of delivering multiple years of therapy.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/10/23 | $90,000,000 | Series C |
New Enterprise Associates RA Capital Management  Samsara BioCapital Vensana Capital Vertex Ventures | undisclosed |
| 06/02/25 | $75,000,000 | Series D |
Gilde Healthcare Partners New Enterprise Associates RA Capital Samsara BioCapital Sands Capital Vensana Capital Vertex | undisclosed |
